贝达药业与晟斯生物达成战略合作 获授FRSW117产品在大中华区域的独家经销权

Group 1 - Company has entered into a strategic cooperation with Jiangsu Shengsi Biological Pharmaceutical Co., Ltd. and Hangzhou Shengsi Biological Pharmaceutical Co., Ltd. to support product development, industrialization, and commercialization [1] - A commercial cooperation agreement has been signed between the company's wholly-owned subsidiary, Zhejiang Beta Pharmaceutical Sales Co., Ltd., and Hangzhou Shengsi Biological, granting exclusive distribution rights for FRSW117 in Greater China [1] - The strategic cooperation framework agreement is a preliminary agreement, with specific cooperation details to be outlined in subsequent agreements, and it is not expected to have a significant impact on the company's 2025 financial results [1] Group 2 - The collaboration aims to enter the recombinant coagulation factor market, further expanding the company's product portfolio in line with its development strategy [2]